Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities.

Trilla-Fuertes L, Gámez-Pozo A, Prado-Vázquez G, Zapater-Moros A, Díaz-Almirón M, Arevalillo JM, Ferrer-Gómez M, Navarro H, Maín P, Espinosa E, Pinto Á, Vara JÁF.

BMC Cancer. 2019 Jun 28;19(1):636. doi: 10.1186/s12885-019-5858-z.

2.

A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses.

Prado-Vázquez G, Gámez-Pozo A, Trilla-Fuertes L, Arevalillo JM, Zapater-Moros A, Ferrer-Gómez M, Díaz-Almirón M, López-Vacas R, Navarro H, Maín P, Feliú J, Zamora P, Espinosa E, Fresno Vara JÁ.

Sci Rep. 2019 Feb 7;9(1):1538. doi: 10.1038/s41598-018-38364-y.

3.

Probabilistic graphical models relate immune status with response to neoadjuvant chemotherapy in breast cancer.

Zapater-Moros A, Gámez-Pozo A, Prado-Vázquez G, Trilla-Fuertes L, Arevalillo JM, Díaz-Almirón M, Navarro H, Maín P, Feliú J, Zamora P, Espinosa E, Fresno Vara JÁ.

Oncotarget. 2018 Jun 12;9(45):27586-27594. doi: 10.18632/oncotarget.25496. eCollection 2018 Jun 12.

4.

Molecular characterization of breast cancer cell response to metabolic drugs.

Trilla-Fuertes L, Gámez-Pozo A, Arevalillo JM, Díaz-Almirón M, Prado-Vázquez G, Zapater-Moros A, Navarro H, Aras-López R, Dapía I, López-Vacas R, Nanni P, Llorente-Armijo S, Arias P, Borobia AM, Maín P, Feliú J, Espinosa E, Fresno Vara JÁ.

Oncotarget. 2018 Jan 8;9(11):9645-9660. doi: 10.18632/oncotarget.24047. eCollection 2018 Feb 9.

5.

Urothelial cancer proteomics provides both prognostic and functional information.

de Velasco G, Trilla-Fuertes L, Gamez-Pozo A, Urbanowicz M, Ruiz-Ares G, Sepúlveda JM, Prado-Vazquez G, Arevalillo JM, Zapater-Moros A, Navarro H, Lopez-Vacas R, Manneh R, Otero I, Villacampa F, Paramio JM, Vara JAF, Castellano D.

Sci Rep. 2017 Nov 17;7(1):15819. doi: 10.1038/s41598-017-15920-6.

6.

Functional proteomics outlines the complexity of breast cancer molecular subtypes.

Gámez-Pozo A, Trilla-Fuertes L, Berges-Soria J, Selevsek N, López-Vacas R, Díaz-Almirón M, Nanni P, Arevalillo JM, Navarro H, Grossmann J, Gayá Moreno F, Gómez Rioja R, Prado-Vázquez G, Zapater-Moros A, Main P, Feliú J, Martínez Del Prado P, Zamora P, Ciruelos E, Espinosa E, Fresno Vara JÁ.

Sci Rep. 2017 Aug 30;7(1):10100. doi: 10.1038/s41598-017-10493-w.

7.

Identification of immune correlates of protection in Shigella infection by application of machine learning.

Arevalillo JM, Sztein MB, Kotloff KL, Levine MM, Simon JK.

J Biomed Inform. 2017 Oct;74:1-9. doi: 10.1016/j.jbi.2017.08.005. Epub 2017 Aug 9.

8.

Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications.

Gámez-Pozo A, Berges-Soria J, Arevalillo JM, Nanni P, López-Vacas R, Navarro H, Grossmann J, Castaneda CA, Main P, Díaz-Almirón M, Espinosa E, Ciruelos E, Fresno Vara JÁ.

Cancer Res. 2015 Jun 1;75(11):2243-53. doi: 10.1158/0008-5472.CAN-14-1937. Epub 2015 Apr 16.

9.

Exploring correlations in gene expression microarray data for maximum predictive-minimum redundancy biomarker selection and classification.

Arevalillo JM, Navarro H.

Comput Biol Med. 2013 Oct;43(10):1437-43. doi: 10.1016/j.compbiomed.2013.07.005. Epub 2013 Jul 13.

PMID:
24034735
10.

A new method for identifying bivariate differential expression in high dimensional microarray data using quadratic discriminant analysis.

Arevalillo JM, Navarro H.

BMC Bioinformatics. 2011 Nov 24;12 Suppl 12:S6. doi: 10.1186/1471-2105-12-S12-S6.

Supplemental Content

Loading ...
Support Center